N. Cammack

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

Sophie Le Pogam, A. Seshaadri, Alan Kosaka et al. · Journal of Antimicrobial Chemotherapy · 2008 · 134 citations

Life Sciences, Genetics, Pharmacology +17

Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

Mike Mink, Sarah Mosier, S. Janumpalli et al. · Journal of Virology · 2005 · 129 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2

Thomas Melby, Prakash Sista, Ralph DeMasi et al. · AIDS Research and Human Retroviruses · 2006 · 66 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Evolution of Genotypic and Phenotypic Resistance during Chronic Treatment with the Fusion Inhibitor T-1249

Thomas Melby, Ralph DeMasi, N. Cammack et al. · AIDS Research and Human Retroviruses · 2007 · 27 citations

Life Sciences, Pharmacokinetics, Pharmacotherapy +17

21 LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO

Sophie Le Pogam, A. Seshaadri, Hee‐Jin Kang et al. · Journal of Hepatology · 2008 · 13 citations · Full text

Life Sciences, Genetics, Microbiology +8